515 A phase 1 study of myeloid modulating agent MTL-CEBPA in combination with pembrolizumab in adult patients with advanced solid tumours

• Ruth Plummer,
• Alessio Cortellini,
• Debashis Sarker,
• Ilian Tchakov,
• John Rossi,
• David Pinato,
• Mikael Sodergren,
• Vikash Reebye,
• Duncan Spalding,
• Nina Raulf,
• Laura Sinigaglia,
• Thomas Talbot,
• Antonio D’Alessio,
• Robert Habib,
• Nagy Habib

Affiliations

Ruth Plummer

Department of Medical Oncology, Northern Centre for Cancer Care, Newcastle Hospitals NHS Trust and Newcastle University, Newcastle upon Tyne, UK

Alessio Cortellini

Division of Cancer, Department of Surgery and Cancer, Imperial College London, London, UK

Debashis Sarker

11 Comprehensive Cancer Centre, King`s College Hospital, London, UK

Ilian Tchakov

10 Eisai, Hatfield, UK

John Rossi

2Kite Pharma, Santa Monica, CA, USA

David Pinato

3Imperial College London, London, UK

Mikael Sodergren

2Imperial College London, London, UK

Vikash Reebye

2Imperial College London, London, UK

Duncan Spalding

2Imperial College London, London, UK

Nina Raulf

4MiNA Therapeutics, London, UK

Laura Sinigaglia

4MiNA Therapeutics, London, UK

Thomas Talbot

2Imperial College London, London, UK

Antonio D’Alessio

2Imperial College London, London, UK

Robert Habib

4MiNA Therapeutics, London, UK

Nagy Habib

4MiNA Therapeutics, London, UK